|
|
Article: Desitin to develop and sell Zogenix' sumatriptan DosePro in EU.(Desitin Pharmaceuticals GmbH)(European Union)(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- March 24, 2008
CopyrightCOPYRIGHT 2008 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Zogenix, a privately-held US specialty drugmaker, has entered into a license agreement to grant exclusive rights in the European Union to Germany's Desitin Pharmaceuticals GmbH to develop and commercialize Zogenix' late-stage, single-use, needle-free product for migraine headache, sumatriptan DosePro. The investigational agent, which incorporates Zogenix' DosePro needle-free drug-delivery technology, has demonstrated bioequivalence to UK drug major GlaxoSmithKline's Imitrex STATdose System ...